- Home
- AXGN vs ATAI Comparison
AXGN vs ATAI Comparison
Compare AXGN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXGN | ATAI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AXGN | ATAI |
|---|---|---|
| Price | $48.18 | $7.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $42.33 | $15.88 |
| AVG Volume (30 Days) | 776.6K | ★ 6.6M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $225,208,000.00 | $4,089,000.00 |
| Revenue This Year | $20.57 | N/A |
| Revenue Next Year | $16.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 20.21 | ★ 1227.60 |
| 52 Week Low | $15.27 | $3.27 |
| 52 Week High | $52.91 | $7.45 |
Technical Indicators
Market Signals| Indicator | AXGN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 66.46 |
| Support Level | $29.48 | $3.56 |
| Resistance Level | $52.91 | N/A |
| Average True Range (ATR) | 2.30 | 0.07 |
| MACD | -0.40 | -0.06 |
| Stochastic Oscillator | 30.89 | 54.76 |
Price Performance
Historical ComparisonAbout AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.